CYPHERPUNK TECHNOLOGIES INC. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $13.43M.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for the quarter ending 2024-12-31 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for the quarter ending 2024-09-30 was $0.00.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for the quarter ending 2024-06-30 was $37.05M.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for fiscal 2024 was $37.05M.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for fiscal 2019 was $12.12M, a 18.07% decline from fiscal 2018.
- CYPHERPUNK TECHNOLOGIES INC. stock issued during period, value, new issues for fiscal 2018 was $14.80M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $13.43M 10-Q · filed 2026-08-12 | |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $37.05M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | |
| 2024-06-30 | $37.05M 10-Q · filed 2025-08-14 | |
| 2020-06-30 | $48.28M 10-Q · filed 2020-08-13 | |
| 2019-12-31 | $12.12M 10-K · filed 2021-03-12 | |
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-13 | $12.12M derived: sum of 4 quarters · filed 2020-08-13 |
| 2019-03-31 | $12.12M 10-Q · filed 2020-05-14 | $12.12M derived: sum of 4 quarters · filed 2020-05-14 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $14.80M 10-K · filed 2020-03-16 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-14 | |
| 2018-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | |
| 2018-03-31 | $14.79M 10-Q · filed 2019-05-15 | |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-13 | |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-11 | |
| 2017-03-31 | $9.05M 10-Q · filed 2017-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |